Navigation Links
Alzheimer’s disease trial With EVT 101 For Successfully Complete

Alzheimer’s disease is a dreaded disease for the elderly. In the direction of its treatment , the effort of Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30, "Evotec") has successfully completed the single ascending dose component // of the Phase I clinical study with EVT 101, a subtype-specific NMDA receptor antagonist Alzheimer's disease.

The study comprised 48 young healthy subjects of whom 36 received EVT 101. These showed that EVT 101 was well absorbed, extremely well tolerated with no significant adverse events and had a good pharmacokinetic profile consistent with once or twice daily oral dosing.

The finding is of great importance as non-selective NMDA antagonists have unfavourable side-effect profile. The EVT 101 has now moved into the multiple ascending dose stage of the Phase I study in both young and elderly volunteers.

EVT 101 is a highly potent and selective antagonist of NR2B subunit containing NMDA receptors.

NMDA receptors are important players in certain pathological disease states such as Alzheimer's disease, Parkinson's disease, neuropathic pain and epilepsy. However, the clinical development of non-selective antagonists has been limited by unfavourable side-effects, such as hallucinations. In the early 1990's it was found that multiple NMDA receptor subtypes exist which contain different NR2(A-D) subunits.

In this direction this trial is stepping stone for success. It would be greatly beneficial in treating patients suffering from Alzheimer’s.


'"/>




Page: 1

Related medicine news :

1. Miracle cure for Alzheimer’s around the corner
2. Vaccine for Alzheimer’s diseas
3. High Cholesterol linked to Alzheimer’s diseas
4. Further support for use of statins in Alzheimer’s disease
5. Catching Alzheimer’s Disease Earl
6. Alzheimer’s Continues to Ris
7. Midlife Brain Activity a Predictor Of Alzheimer’s Diseas
8. New Drug Combination Found To Improve Memory in Alzheimer’s Patient
9. Blood Pressure An Early Warning Sign Of Alzheimer’s Disease
10. Delaying The Progression Of Alzheimer’s Disease
11. Hope For Patient With Alzheimer’s Diseas
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/24/2017)... ... ... The University of Iowa, long recognized as one of the top research ... teachers with the specific skills and training they need to teach English as a ... and HigherEducation.com is working to ensure that this new program is available to the ...
(Date:1/24/2017)... CA (PRWEB) , ... January 24, 2017 , ... The ... good news for everyone and particularly good news for prostate cancer patients: incidents of ... diagnosis. , According to the report the cancer death rate has dropped from its ...
(Date:1/24/2017)... Pass, OR (PRWEB) , ... January 24, 2017 ... ... Gerald H. Pollack, Ph.D., http://www.faculty.washington.edu/ghp , Sharon Kleyne, the nation’s foremost ... of Water, Global Climate Change and Your Health on Voice America, once again ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... unveiled its latest award-winning bottles, designed specifically to optimize the drinking experience for ... Agua is renowned for introducing the world’s first untouched bottled water purposed exclusively ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... a leading natural supplement for relieving premenstrual syndrome, or PMS . , ... some point. These symptoms can include cramps, constipation, irritability, headaches, fatigue, and other ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... PUNE, India , January 24, 2017 ... Allied Market Research, titled, "Cold Chain Logistics Market by ... & Frozen Dessert, Meat, Fish & Sea Food, Drugs ... Industry Forecasts, 2014-2022," projects that the global cold chain ... 2022, growing at a CAGR of 16% (2016 to ...
(Date:1/24/2017)... January 24, 2017 Analysis of the Liquid ... Liquid Biopsies - our new study reveals trends, R&D progress, ... If you are involved in this sector you must read this ... revenues streams to 2027, assessing data, trends, opportunities and business prospects ... Discover How ...
(Date:1/24/2017)... GAITHERSBURG, Md. , Jan. 24, 2017 /PRNewswire/ ... leader in the engineering and industrialization of biology to improve ... announced that it has entered into a definitive agreement to ... a clinical-stage company and pioneer in the development of AdenoVerse™ ... and expand upon GenVec,s expertise in adenoviral vectors and cGMP ...
Breaking Medicine Technology: